Jay Hallinan Appointed Chief Commercial Officer of Q’Apel Medical

Q’Apel Medical (Q’Apel), a private medical device company focused on revolutionizing neurovascular interventions, announced today the appointment of seasoned medical device executive Jay Hallinan as Chief Commercial Officer.

In this role, Jay Hallinan will lead the company’s global sales and marketing organization, oversee Q’Apel’s commercial strategy and drive revenue growth across Q’Apel’s expanding product portfolio.

“I am excited to join Q’Apel at this important time as the company looks to amplify its commercial activities,” commented Hallinan. “The team has developed an impressive portfolio that uniquely addresses the needs of clinicians performing delicate neurovascular interventions. I look forward to working together to accelerate our commercial efforts and build a solid foundation for future growth.”

With over two decades in the medical device industry, Hallinan brings extensive sales and management experience. Most recently, he served as the Vice President of North America for Stryker where he was responsible for the regional sales strategy and structure, new business development, contract negotiation and market position. Prior to that position, Jay Hallinan held commercial positions of increasing responsibility within Stryker’s organization as well as leadership positions with Boston Scientific and Medtronic. He also served as CEO of Tenex Health. Hallinan is a graduate of the University of Georgia and received his M.B.A. from the McColl School of Business at Queens College.

“I am thrilled to welcome Jay to the Q’Apel team. He is a strong leader with a proven track record of commercial success which will be critical as we look to expand our portfolio and strengthen the company’s position within the neurovascular market,” commented Jodie Fam, CEO of Q’Apel Medical. “With a focused discipline on execution, Jay’s expertise will add tremendous value and makes him an ideal fit to spearhead our commercial operations.”

 

Hot this week

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."